Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Afatinib in NSCLC With HER2 Mutation (NICHE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02369484
Recruitment Status : Completed
First Posted : February 24, 2015
Results First Posted : March 1, 2019
Last Update Posted : July 31, 2019
Sponsor:
Information provided by (Responsible Party):
European Thoracic Oncology Platform

Brief Summary:
The purpose of this study is to investigate the control of disease in pretreated patients with advanced non small cell lung cancer (NSCLC) harbouring HER2 exon 20 mutations as well as the safety and tolerability (how severe the side effects are) of the treatment with afatinib.

Condition or disease Intervention/treatment Phase
NSCLC Drug: Afatinib Phase 2

Detailed Description:

Previous clinical studies of NSCLC have shown that patients with tumors harboring specific gene mutations (changes) in the epithelial growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) showed better results after treatment with tyrosine kinase inhibitors (TKI), like afatinib (tradename Giotrif®) , compared with classical treatment with chemotherapy. The treatment with TKI has become a new standard-of-care for patient with advanced lung cancer and EGFR or ALK changes. Several novel mutations, which are candidates as targets for specific medication have been discovered. Human epidermal growth factor 2 (HER2, erbB-2/neu) is a protein of the so called ErbB family (including HER2 [ErbB2], ErbB3 and ErbB4). These proteins are involved in the growth and spread of cancer cells. Mutations in HER2 are found in about 2% of the NSCLC.

Afatinib works by blocking the activity of the ErbB family proteins and can inhibit growth and spread of cancer cells. Afatinib is approved by the European and the Swiss Medicines Agencies for the treatment of adult patients with a specific type of cancer of the lung (non-small cell lung cancer) that is identified by a change (mutation) in the gene for EGFR as first treatment or if prior chemotherapy treatment has been insufficient.

A total of 22 patients from centers around Europe are expected to be enrolled in this study over a period of 24 months.

All patients will be treated in the same way. The study will take approximately 40 months to be completed.

This clinical trial is conducted according to the applicable national laws and international guidelines.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Afatinib in Pretreated Patients With Advanced NSCLC Harbouring HER2 Exon 20 Mutations
Actual Study Start Date : September 16, 2015
Actual Primary Completion Date : September 15, 2017
Actual Study Completion Date : September 15, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Afatinib
Afatinib 40 mg p.o./day until tumour progression or lack of tolerability
Drug: Afatinib
40mg p.o./ day until documented progression or unacceptable toxicity
Other Names:
  • Giotrif
  • BIBW 2992




Primary Outcome Measures :
  1. Disease Control (Defined as Complete or Partial Response, or Disease Stabilisation Lasting at Least 12 Weeks) [ Time Frame: at interim (after the first 9 pts have been followed for 12 weeks) & final analysis (approx. 40 months after inclusion of first pt) ]

    Disease control (DC) is defined as complete or partial response, or disease stabilisation lasting at least 12 weeks.

    Disease control will be determined using RECIST 1.1 criteria:

    Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.

    Progression (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on the trial. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions denotes disease progression.

    Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters recorded on the trial.



Secondary Outcome Measures :
  1. Progression-free Survival [ Time Frame: Time assessed from the date of enrolment until documented progression or death (max 36 months) ]
    Progression-free survival (PFS) is defined as the time from date of enrollment until documented progression or death, if progression is not documented. Censoring will occur at the last tumor assessment only if patients is lost to follow-up

  2. Objective Response [ Time Frame: Assessed across all time-points during the period from enrolment to termination of trial treatment (max. 36 months) ]

    Objective response is defined as best overall response (CR or PR) across all assessment time-points during the period from enrollment to termination of trial treatment. Objective response to afatinib treatment will be determined using RECIST 1.1 criteria:

    Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.

    Progression (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on the trial. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions denotes disease progression.

    Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters recorded on the trial.


  3. Overall Survival [ Time Frame: Time assessed from the date of enrolment until death (max 36 months) ]
    Overall survival (OS) is defined as the time from the date of enrollment until death from any cause. Censoring will occur at the last follow-up.

  4. Toxicities of Treatment [ Time Frame: Assessed from the date of informed consent until 90 days after the final dose of afatinib (max 18 months). ]
    Adverse events classified according to NCI CTCAE version 4.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed non small cell lung cancer
  • Stage IIIB (non amenable to curative-intent multimodal treatment) or IV NSCLC, according to 7th TNM classification.
  • Contrast-enhanced CT of thorax and upper abdomen (incl. liver, kidney, adrenals);
  • brain MRI or CT within 28 days before the date of enrolment.
  • Non-predominant squamous subtype (<50% squamous cells).
  • Previous treatment with a platinum based chemotherapy for advanced disease; or Disease relapse or progression within <6 months after adjuvant platinum based chemotherapy, or (definitive) platinum-based chemo(radio)therapy for stage I-III NSCLC
  • Measurable or evaluable disease (according to RECIST 1.1 criteria). Not eligible: patients with only one measurable or evaluable tumour lesion which was resected or irradiated prior to enrolment.
  • Locally documented HER2 mutation
  • Age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
  • Life expectancy >3 months.
  • Adequate haematological function:
  • WBC ≥ 2000/μL
  • haemoglobin ≥ 9 g/dL
  • neutrophils count ≥1.5×109/L
  • platelet count ≥ 100 × 109/L
  • Adequate liver function:
  • Total bilirubin ≤ 1.5 × ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
  • ALT < 2.5 × ULN
  • AST < 2.5 × ULN
  • GGT < 2.5 × ULN.
  • Adequate renal function: Calculated creatinine clearance ≥ 45mL/min (Cockroft-Gault)
  • Patient capable of proper therapeutic compliance, and accessible for correct followup.
  • Women of childbearing potential (< 1 year without menstruation or < 2 years without menstruation following chemotherapy) must have a negative serum or urine pregnancy test within 7 days before beginning trial treatment.
  • Sexually active men and women of childbearing potential must use an effective contraceptive method (two barrier methods or a barrier method plus a hormonal method) during the trial treatment and for a period of at least 28 days following the last administration of trial drug.
  • Recovered from any previous therapy related toxicity to ≤Grade 1 at date of enrolment (except for recovery to ≤Grade 2 of alopecia, fatigue, creatinine increased, lack of appetite as well as stable sensory neuropathy)
  • Written Informed Consent (IC) for trial treatment must be signed and dated by the patient and the investigator prior to any trial-related intervention.
  • Tumour block available for central review of HER2 mutation status.

Exclusion Criteria:

  • Patient with mixed small-cell and non-small-cell histologic features
  • Uncontrolled lepto-meningeal metastatic disease. Radiotherapy-treated or asymptomatic brain metastases are allowed (no systematic screening). Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids or have been on stable dose of corticosteroids for at least 4 weeks before starting trial treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before date of enrolment.
  • Previous treatment with HER2 targeted antibody or tyrosine kinase inhibitor including afatinib.
  • Major surgery within 4 weeks before starting trial treatment or scheduled for surgery during the projected course of the trial.
  • Patient who has had in the past 3 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ ductal carcinoma of the breast.
  • History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of III or IV (see Table 2 below), unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to enrolment.
  • Patient with other serious diseases or clinical conditions, including but not limited to uncontrolled active infection and any other serious underlying medical processes that could affect the patient's capacity to participate in the trial.
  • Known HIV, active Hepatitis B or Hepatitis C infection (screening not required).
  • Known or suspected hypersensitivity to afatinib or any of its excipients.
  • Interstitial lung disease or pulmonary fibrosis.
  • Women who are pregnant or in the period of lactation.
  • Patients with any concurrent systemic anticancer therapy.
  • Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption.
  • Patient who received treatment with an investigational drug agent during the 3 weeks before enrolment in the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02369484


Locations
Layout table for location information
Germany
Universitätsklinikum Köln
Köln, Germany
Netherlands
NKI-AVL
Amsterdam, Netherlands
Spain
Vall d'Hebron University Hospital
Barcelona, Spain
Switzerland
CHUV
Lausanne, Switzerland
USZ
Zürich, Switzerland
Sponsors and Collaborators
European Thoracic Oncology Platform
Investigators
Layout table for investigator information
Study Chair: Solange Peters, MD-PhD Centre Hospitalier Universitaire Vaudois (CHUV); Lausanne, Switzerland
Study Chair: Rafal Dziadziuszko, MD Medical University of Gdansk, Gdansk, Poland
  Study Documents (Full-Text)

Documents provided by European Thoracic Oncology Platform:
Statistical Analysis Plan  [PDF] January 23, 2017
Study Protocol  [PDF] December 1, 2014
Informed Consent Form  [PDF] December 1, 2014

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: European Thoracic Oncology Platform
ClinicalTrials.gov Identifier: NCT02369484    
Other Study ID Numbers: ETOP 7-14
2014-005098-35 ( EudraCT Number )
1200.230 ( Other Identifier: Boehringer Ingelheim )
SNCTP000001674 ( Registry Identifier: Swiss National Clinical Trials Portal (SNCTP) )
First Posted: February 24, 2015    Key Record Dates
Results First Posted: March 1, 2019
Last Update Posted: July 31, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by European Thoracic Oncology Platform:
Stage IIIb/ IV NSCLC harbouring HER2 exon 20 mutations
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Afatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action